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1  research, meDicine anD imProvements in health care:   
 Placing genetic research in context
Research is one of the central building blocks upon which modern medicine is based. 
Evidence-based research into treatments, new tools of diagnosis and pharmaceutical 
interventions have led to an improved quality of life and new and significant 
improvements in methods of treatment. As early as the fourth century BC, the 
Hippocratic Oath noted that, due to the ‘uncertain’ nature of medicine, in order to 
devise new treatments physicians were allowed to attempt new and untried remedies, 
so long as they maintained the maxim ‘benefit and do no harm’.1 The twelfth century 
philosopher and physician Moses Maimonides pleaded that he be granted the 
strength, time and opportunity to correct the knowledge he had acquired and to 
endeavour to ‘extend its domain’.2 
Until the development of important diagnostic aids, for example the microscope 
(seventeenth century), the thermometer and new methods of chemical analysis of the 
blood (eighteenth century) and x-rays (nineteenth century), the practice of medicine 
was severely restricted compared to today. That is not to say that medicine has not been 
a specialised discipline for a significant period of time. The oldest medical records 
date from around 2600 BC. Physicians not only existed in ancient Egypt, but were also 
divided into specialties we still see today (obstetricians–gynaecologists, proctologists, 
ophthalmologists, dentists and surgeons).3 It is only recently, however, in terms of 
medical history that medicine has ceased to be ‘practiced against a background of 
incomplete scientific knowledge about the nature of disease process’.4 Medicine (at 
least up until the early nineteenth century) was considered more of an ‘art’ than a 
‘science’, and until the nineteenth century medical understanding of disease relied 
almost entirely on a doctor’s clinical skills at the bedside, supplemented with a 
knowledge of biology and autonomy that could be gained in the autopsy room.5 
One of the most significant contributions to the practice of medicine occurred in the 
eighteenth century: the introduction of the concept of evidenced-based medicine by 
English physician Thomas Beddoes (1769–1808). Beddoes’ primary concern was that 
medicine had become ‘stagnant and secretive’. He advocated two solutions to this 
problem. First, he proposed the ‘systematic collection and indexing of medical facts’ 
which could be compared in order to ‘sift good practice from bad’; and, secondly, 
he urged other physicians to publish their findings (presumably both the beneficial 
and the harmful) more often so that others could learn from previous practice.6 
Beddoes believed that medicine was harming patients by its failure to collect and 
analyse information about what practice worked best in the treatment of patients. He 
presupposed not only that it was morally right to collect data and share it between 
physicians, but also that there was a duty to do so, if that information could be used 
to benefit the patient.7 One of the most significant early uses of statistical analysis 
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in medicine was undertaken by the French clinician Pierre Charles Alexandre Louis 
(1787–1872), who used it as a basis to prove that the practice of ‘bloodletting’ which 
had been a significant part of medical practice up until that time was not only non-
beneficial, but ‘positively harmful’ in the treatment of disease.8 
History tells us, therefore, that progress in medicine and scientific knowledge about 
the body and how it operates is crucial to mankind. While the ancient Egyptian 
physicians may have provided relief for their patients with their array of medicines, 
the linking of medical treatment with charms, incantations, amulets and prayers may 
have had little real therapeutic value. One of the continuing struggles in medical 
practice is how to improve the health and well-being of the patient, while minimising 
harm. As Beddoes and Louis envisaged, researching which practices worked and 
which did not was the first step. Following on from this, however, was a new method 
of scientific endeavour, the age of the physician–scientist who not only sought to 
treat the patient’s illness, but also to broaden understanding of disease with trials 
of new methods of treatment. This new era, involving experimentation on humans, 
brought advances in medicine along with new ethical challenges. 
1.1  human experimentation in the name of medicine: ‘therapeutic’ research   
 versus ‘pure’ scientific investigation9 
To develop new treatments and methods of diagnosis it was necessary for physicians 
to develop techniques for research. In the ‘Age of Enlightenment’, during the 
eighteenth century, the scientific revolution continued and eventually shaped 
modern medicine with important progress taking place in the biological sciences.10 
Since the mid eighteenth century the number of experiments on human subjects has 
increased. These early ventures into controlled research trials resulted in significant 
improvements in medical practice, providing medical treatments for scurvy (Lind, 
1757), the vaccination for smallpox (Jenner, 1798) and an understanding of the 
circulation of the blood (Harvey, 1628).11 Despite the obvious benefits of research, it 
is not without its risks. History records that at times medical research became a form 
of medical experimentation that was not in the interests of the patient but rather of 
medical science. 
At times there is a blurring of the boundaries between research and innovative 
medical practice. Although research and practice can occur together, ‘practice’ is 
commonly now used to refer to medical interventions designed purely to ‘enhance 
the well-being of an individual patient’ and which have a ‘reasonable expectation of 
success’. Contrastingly, the term ‘research’ applies to investigations designed to ‘test 
an hypothesis, permit conclusions to be drawn, and thereby to develop or contribute 
to generalizable knowledge’ which may be expressed in ‘theories, principles, and 
statements of relationships’.12 
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Human experimentation has been defined as ‘anything done to an individual to 
learn how it will affect him’.13 The main objective of human experimentation is 
to acquire new scientific information, rather than directly benefit the individual. 
While the terms ‘research’ and ‘experimentation’ are often used interchangeably, a 
distinction can be made. Research can be taken to apply to investigations conducted 
in accordance with a predetermined protocol, while experimentation (in contrast) 
refers to more speculative investigations, which adopt a more ‘ad hoc’ approach to 
the individual subject.14 Following the Nuremberg medical prosecutions, the full 
dangers became known of physicians sacrificing the interests of their patients to 
scientific endeavour. The World Medical Association responded by developing a 
Code of Practice for doctors, outlining the ethics of human experimentation. Central 
to the Declaration of Helsinki was the statement that ‘the health of my patient will be 
my first consideration’.15 This marked the first time a distinction was drawn between 
clinical research that was therapeutic, and research that was ‘pure’ clinical research, 
aimed primarily at acquiring new scientific information.16
Genetic studies such as those discussed later fall in many cases between these two 
categories. In most cases there will be no direct benefit to the research participant 
donating the sample for genetic analysis. The major benefit will most likely come 
from the development of a greater understanding of the relationship between genetic 
variation and disease, together with a fuller understanding of the complex interaction 
between genetic and environmental factors and their influence on health status 
generally. The information from this may, in the future, help to prevent and treat 
some diseases, but it is important to distance these long-term potential benefits from 
any perceived short-term direct benefit to the participant. On the other hand, medical 
genetic research involves only minimal harm to the participant if we think of harm 
in the purely physical sense. What biomedical genetic research does carry, however, 
are new kinds of harm from those traditionally considered in research ethics. These 
are harms to the psychological, emotional, cultural and (in some cases) economic 
well-being of the research participant. In the case of research on population-based 
groups, these harms can also include socio-political harms of the type not previously 
considered in research ethics. 
2  researching the human genome 
Research into human genetic variation has been gathering pace in the nineteenth 
century. This research was aimed at identifying the genetic basis for disease, and initially 
began by identifying genetic anomalies responsible for some of the commonest forms of 
Mendelian conditions. In 1938 British physician Lionel Penrose discovered the genetic 
origin of the condition phenylketonuria. Linus Pauling observed the biochemistry of 
haemoglobin in sickle-cell disease in 1949. Following the determination in the 1950s 
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of the exact number of chromosomes, more studies revealed the link between genetics 
and disease. These new investigations combined statistical genetics, cytology and 
biochemistry, and marked a new era in genetic research.17 
Between 1981 and 2000, a total of 1112 genes were discovered which harboured 
mutations leading to monogenic diseases.18 Among the most serious disorders caused 
by single-gene defects are cystic fibrosis, Duchenne muscular dystrophy, Huntington 
disease, the thalassaemias, sickle-cell disease, haemophilia and some uncommon 
hereditary cancers. As more research is undertaken on the human genome, it is 
increasingly clear that most common diseases have a genetic component.19 Not all forms 
of genetic research are the same, and we should reconsider the assumption that one 
set of moral standards could act as a guidance for all types of genetic research. Genetic 
research to identify an autosomal recessive condition (such as cystic fibrosis) using 
family linkage studies may raise very different moral concerns from genetic research, 
on a targeted sub-population, into multifactorial conditions which focuses on the 
complex working of single nucleotide polymorphism (SNP) variation. Significantly, 
the outcomes from different genetic research may be quite distinct. While to date one 
of the most prominent uses of genetic information is in the context of reproduction 
(see Human Genome Research Project, Choosing Genes for Future Children: Regulating 
Preimplantation Genetic Diagnosis (Dunedin, New Zealand: Human Genome Research 
Project, 2006)), there are other potential uses of genetic information, such as to create 
an ‘envirogenetic’ profile, or to generate pharmaceuticals that will work optimally 
with an individual’s unique genetic makeup (pharmacogenetics).
While current uses of genetic information focus on how that information can be used 
to avoid the genetic condition being passed on to offspring (for example, prenatal 
testing or preimplantation genetic diagnosis (PGD)), or to assist in diagnosing a serious 
hereditary disease (such as Huntington disease or sickle-cell anaemia), new genetic 
information may be useful to help individuals reduce their life-time risk of suffering 
from some of the most common and life-threatening diseases (such as heart disease, 
cancers, stoke and diabetes). In these latter cases, those at increased genetic risk can 
choose to make lifestyle changes.20 While modern medicine can alleviate symptoms 
and prolong life for sufferers of these common ailments, it cannot yet cure them. One 
of the greatest challenges to modern medical practice has been its powerlessness against 
some of the most significant diseases of the twentieth century such as heart disease 
and cancer. While we know we can alter our lifestyle to reduce our risk of cancer, the 
absence of a cure seems at odds with the promise of what medicine would provide. In 
a century that began with some of the most significant improvements in health status 
following remarkable advances in medicine (consider the disappearance of diphtheria 
and poliomyelitis, the development of sophisticated diagnostic aids, the development 
of life-support systems and modern surgery, organ transplantation, chemotherapy 
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and the development of insulin) it seems that the reality of what medicine can do to 
fight these major killers is out of step with our expectations.21 
Mapping of the human genome promised to provide a new range of information that 
was not available a decade ago. This information alone will not improve health or 
prevent disease. Advances of these kinds will come only after a deeper understanding 
of what this information means, and how genetic material controls the body at a 
molecular level.22 This first kind of research is already established, and has contributed 
some of the most significant advances in our understanding of genetics and health to 
date. Since many conditions are a result of both genes and environment, however, a 
second way to understand what the genetic data means is to gather genetic material 
from large numbers of persons and, over time, track their health states and disease 
outcomes, and map these against basic biographical information about how they live 
(such as their diet, exercise and living environment).23 
2.1  the role of polymorphisms2
The human genome is made up of around 25,000 genes. If we compare the DNA of 
two different people we find a variation in genetic material at an average rate of 1 per 
1250 base pairs.25 Variations from a predominant allele occurring at an incidence of 
>1 per cent are called genetic polymorphisms.26 Some polymorphisms will have no 
significance in terms of health status, but others will have a role to play in determining 
how an individual develops and responds to environmental factors. The frequency of 
a polymorphism can vary between different population subgroups.27 
‘Polymorphism’ is the name given to the small variations that occur in the sequences 
of bases in the genetic makeup of different people. As shown in Table 1, they can 
include either a change in a base pair at an isolated point along the genome (or SNP), 
or an alteration in the number of bases at different points along the genome (called a 
length polymorphism).28 The most common polymorphism is the SNP. The majority 
of SNPs have two alleles, representing the substitution of one base for another (a C 
to T or A to G).29 The number of SNPs in the human genome makes them suitable 
for generating ‘ultra-fine-resolution genetic maps’; although, as a result of their 
abundance, there is no guarantee that the genetic map will be powerful enough to 
predict all disease association states.30 There are many correlations between SNPs, 
making it difficult to distinguish the SNP that is associated with a phenotype from the 
other SNPs associated with it.31 Many association studies use SNPs, however, due to 
their potential to be genotyped on a large scale using new methods of automation.32 
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TYPES OF POLYMORPHISM
Single nucleotide polymorphism (SNP)
 ATTCCTTGGTATC ATTCCTCGGTATC
 TAAGGAACCATAG TAAGGAGCCATAG
(e.g. a T–C substitution, forcing an A–G change in the other strand)
Length polymorphism
short tandem repeats (STRs) or variable number tandem repeats (VNTRs)
 GTATATATATATATATAC GTATATATAC
 CATATATATATATATATG CATATATATG
 (eight TA repeats) (four TA repeats)
Table 1:  Types of polymorphism 
Source: Select Committee on Science and Technology, Human Genetic Databases: 
Challenges and Opportunities (2001) Appendix 7, Box 9
These variations can occur due to mistakes in the way DNA is copied during cell 
division, through damage to DNA (by for example chemicals or radiation) or, in 
the majority of instances, through the different combination of mixtures of DNA 
from two parents that occurs during sexual reproduction.33 Some polymorphisms 
can create benign differences between individuals (such as eye colour and other 
distinctions in appearance), while others can affect a person’s health.34 Much 
research is now focused on polymorphisms that create a susceptibility to disease. 
In other words, the polymorphism does not make it inevitable that an individual 
will develop a particular condition (such as cancer or heart disease), but may make 
it more likely that, with the presence of other factors (such as poor diet, lack of 
exercise and environmental factors such as exposure to chemicals that trigger the 
disease), the individual will have an increased risk of developing the disease.35 In 
some cases differences in polymorphisms may affect how some individuals respond 
to medications.36 It is anticipated that an increased knowledge of polymorphisms 
will allow drug therapy to be tailored to coincide better with an individual’s genetic 
makeup, thereby increasing its efficiency. 
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  ethical issues arising From genetic research 
.1  non-therapeutic research: special issues in genetics7 
The sequencing of the human genome provides data about our genetic makeup, but 
does not necessarily translate into immediate health benefits.38 While some benefits 
may soon be available, many others will take years before they are realised. This 
poses special problems when we consider genetic research, much of which may be 
of a ‘non-therapeutic’ nature. As the United Kingdom Human Genetics Commission 
has succinctly described, ‘[r]eserach in human genetics relies upon early-stage work 
with no direct medical relevance. In this sort of work, sometimes known as “blue 
skies” research, the objective is to understand gene function rather than to pursue 
immediate practical goals’.39
The time lag between the time when we gain knowledge of our genetic sequence and 
the later time when this knowledge translates into a health benefit has been termed 
the ‘therapeutic gap’. This interval between pure scientific discovery and therapeutic 
benefit has caused some to issue guarded warnings about how we promote genetics, 
at the very least with regard to the exercising of caution when potentially creating 
unrealistic expectations in the mind of the public about what genetic research can 
deliver in terms of immediate health gains. As the House of Lords Select Committee 
on Science and Technology concluded in its deliberations on possible benefits, with 
a call for prudence in relation to genetics:40 
We fear that recent publicity may have led to misplaced expectation that benefits 
will be realised quickly. Accordingly, we urge that the Government and all those 
involved in explaining this complicated science to the public should, while 
stressing the benefits of research on human genetic databases, ensure that the 
likely time scales and other potential consequences are made clear.
Genetic research relies heavily on the donation of human genetic material for analysis. 
These samples are donated from research participants. Some samples will be donated 
by participants at known risk of genetic disease. They may either have a medical 
condition, the genetic origin of which is being researched, or they may be closely 
related to an individual who is known to have the condition in question. Initial 
investigations into the genetic nature of disease comprised these types of studies, 
known as ‘linkage studies’, in which researchers started gathering genetic material 
from known sufferers and expanded their pool of research participants to wider 
family members. In these cases, although the ‘therapeutic gap’ means that direct 
health benefits (in terms of improved treatments) may be a long way off, the research 
studies do offer some potential benefits to participants. First, they offer predictive 
testing which can be used to detect susceptibility for some hereditary conditions 
(such as the BRACA-2 gene which can be used as a predictive for some forms of 
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breast cancer). Secondly, research may lead to improved diagnosis, as in the case of 
the over 1100 disease-related genes (many are single-gene disorders), which allows 
‘at-risk’ couples to use genetic screening to avoid the birth of a child affected by an 
identifiable genetic disorder.41 
For conditions with a more complex mode of inheritance (see Table 2), where there 
is a complicated interaction between disease and environment, the form of genetic 
research may take a different direction. While it is still crucial to obtain genetic 
samples for analysis, this type of research typically differs from the traditional linkage 
studies in two ways. First, this research may not focus on obtaining participants from 
known at-risk family groups, but may instead seek to obtain samples from a range 
of people, many of whom may be selected from the general public rather than a 
select group of participants. Secondly, these studies require a high degree of personal 
information about influences such as the participants’ health status, lifestyle, diet 
and environmental factors. This type of research therefore requires ‘long-term 
epidemiological studies of large numbers of people … to unravel the links between 
genetic background, environmental (or lifestyle) factors and the occurrence of 
disease’.42 It may also increasingly require the establishment of large-scale genetic 
databanks, a relatively new phenomenon in genetic research. 
ENVIRONMENTAL AND GENETIC INFLUENCES ON DISEASE
 Wholly environmental Environmental/genetic Wholly genetic
 ‘Accidents’ ‘Complex diseases’ ‘Monogenetic disease’
 Chemical poisoning Asthma Huntington disease 
 Radiation sickness Obesity Haemophilia  
  Heart disease
  Breast cancer 
Table 2: Environmental and genetic influences on disease 
Source: Select Committee on Science and Technology, Human Genetic Databases: 
Challenges and Opportunities (2001) Chapter 3, para 3.6
While research into complex diseases does not subject the participants to physical 
procedures evident in other forms of research (such as drug trials), it does involve 
the collection and retention of highly personal information, both genetic and non-
genetic.43 In this type of research any potential benefit to the participants may be 
hard to identify. ‘Participants in genetic research may therefore be invited to take part 
in projects in which the findings will only be predictive at the population level and 
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which the benefits for the community may be distant and uncertain’.44 This type of 
research may aid in disease prevention, for which the best preventative measures in 
the case of common disorders may be dietary or lifestyle changes, rather than drug 
therapy or sophisticated medical intervention.45 
Research of this kind heralds a turning point in human genetic research. Not only does 
it involve sequencing large sections of an individual’s unique genome, it requires this 
information to be held in a centralised database, and checked against highly personal 
biographical information. In addition to questions of consent, privacy, storage and 
use of such personal information, it also raises key issues around the benefits that this 
type of research offers participants. Is this type of research of potential ‘therapeutic’ 
benefit to the participant, or is it the ‘pure’ research type identified by the World 
Medical Association, aimed at acquiring new scientific information? The ethics 
around such research are further complicated when those targeted individuals belong 
to one identifiable sub-population in society. In these situations questions of benefit 
and potential harm extend beyond the individual researcher and research-participant 
relationship. The implications for the wider community, and those connected by the 
genetic material collected for research purposes, must also be considered. 
While this new form of genetic research may seem to tend towards the ‘pure science’ 
end of the spectrum as far as research goes, the research is generally considered both 
scientifically valuable and ethically acceptable, so long as it is conducted in accordance 
with ethical standards – many of which have struggled to keep pace with new forms 
of research. Genetic research that promises to provide benefits at a community rather 
than individual level is tacitly supported and recognised as a potentially valuable field 
of investigation. The American Society of Human Genetics, for example, in its Code 
of Practice calls on members to ‘promote public health, through the advancement 
of human genetic research and the provision of high quality genetic services’.46 In 
the United Kingdom the Human Genetics Commission (HGC) describes this type 
of research as ‘vital’, and emphasises that ‘as many people as possible should feel 
able to participate in genetic research, confident of the security and confidentiality 
of their personal genetic information and confident too, that ethical standards in 
research will be upheld’.47 Since many of these research projects involve the creation 
of genetic databases, new ethical standards have developed to ensure that genetic 
and personal information is protected to a satisfactory level.48 In a few cases specific 
targeted legislation has been passed to regulate genetic databases (such as those of 
Iceland and Estonia). In most cases, however, national bioethics bodies have issued 
a comprehensive range of reports and recommendations to provide guidance in 
this area (such as in France, the United Kingdom, Canada and the United States).49 
The World Health Organization is currently working towards a comprehensive set 
of recommendations and guidelines for researchers and research ethics committees 
worldwide.50 The World Health Organization currently recommends that, in the case 
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of research seeking to create a database, the onus is on the researcher to justify its 
‘nature, purposes, content, and uses’.51
 
.2  recruitment
Most of the advancements in genetics to date have been in relation to identification 
of those genes that contribute to diseases which are highly penetrant and are caused 
by single genes (such as cystic fibrosis). The main method by which these genetic 
links to disease were discovered was through family linkage studies.52 For these 
studies many of those participating in the research were already patients or family 
members of patients. A study which restricts recruitment of participants to patients 
‘introduces a potential selection bias because their health status could cause them 
to be more motivated to participate in a research study compared with members of 
the general population’.53 As a result, it is argued that follow-up studies of patient 
participants and their perspectives on aspects of the research procedure (such as 
informed consent) may not accurately represent the views of the general population 
about participation in population-based research.54 
Current genetic research, however, focuses on conditions that have a more complex 
etiology. What has proved difficult is the location of those genes that contribute to 
common diseases such as diabetes, heart disease and cancer. In the case of these 
conditions, the phenotypes are affected by not one gene but many, each having a 
small effect, together with the environment.55 A new method of genetic research 
is therefore required: one which performs genetic analysis on a large number of 
participants, some affected and some not. Enrolling such a wide range of research 
participants poses new challenges for researchers. Resistance to these studies has 
occurred in some cases for a number of reasons, including fears about the misuse 
of information, confidentiality concerns, general fears of involvement with ‘genetic 
studies’ or an unwillingness to be involved in genetic reseach per se.56
Box 1: guiDance For researchers recruiting relatives oF 
ParticiPants For research PurPoses
researchers wishing to recruit relatives of participants to the research must 
consider any potential for harm which might result from an attempt to recruit, 
and in doing so, should take into consideration the privacy and any known 
sensitivities of the relatives, and accepted processes of communication with the 
family. in general, recruitment should be through a family member who is already 
a participant in the research.
Source: Winship and Marbrook. Ethical Considerations Relating to Research in 
Human Genetics, 1998 (amended 2000)
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Special concerns arise in relation to genetic studies involving population-based 
groups. While it may be tempting to obtain initial consent from group leaders (in 
cases where the targeted population belongs to a culturally or ethnically defined 
group) these persons may not be (or be perceived to be) entirely neutral in their views 
of the research. The role that community leaders should play in being the ‘gateway’ 
to genetic services has received much ethical attention. Issues of consent within the 
group and pressures within a targeted community to consent to research are some of 
the most complex ethical concerns arising from genetic research. These are discussed 
more fully later in this Report. 
.  informed consent
3.3.1 Information that should be provided
Consent is a crucial feature of any research on human subjects, as recognised by 
article 5(b) of the Universal Declaration on the Human Genome and Human Rights 
(1999) and article 8 of UNESCO’s International Declaration on Human Genetic 
Data (2003). Consent is valuable for two main reasons. First, it provides the research 
participant with the information necessary to make an informed decision about 
whether to become involved in the research project. Secondly, it serves to remind 
the investigators of the ethical duty not only to advise the research participant of 
potential harms, but also to become aware themselves of potential dangers and 
to take steps in the development and design of any research protocol formulated 
to minimise potential harm to participants.57 The principle of informed consent 
is firmly entrenched in medical ethics, and is a founding principle upon which 
any medical practice is based. Consent consists of three basic components: that 
adequate information is provided to enable an informed judgment to be made; that 
information is provided in a form and manner that will enable it to be understood by 
each individual; and that the consent is voluntary in nature (participation free from 
manipulation, coercion, inducement or any other undue influence).58 Participants in 
any research study must be advised of the purpose, intended outcomes or benefits (to 
the individual and the community) of the treatment or research; all foreseeable risks, 
side effects or potential harm that are material to the research participants; and the 
right to withdraw from the research.59 
3.3.2  Questions of coercion and group participation
Participation in research must be voluntary and not subject to either coercion or 
inducement through either direct or indirect means. New Zealand’s Operational 
Standard for Ethics Committees takes a broad view of what may constitute such 
coercion, stating that it includes ‘financial or other rewards (such as promises of 
treatment), exploiting the vulnerability of individuals, or the influence and status 
of the health professional or researcher’.60 Any reimbursement for participation 
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must be reasonable (such as covering the participant’s expenses) and not amount 
to an ‘inducement that compromises the voluntary nature of an individual’s 
participation’.61 
When genetic research is conducted by medical professionals or public health bodies 
with whom the participant has an ongoing relationship, the role of consent can 
become obscured by other factors causing new ethical challenges. Results from one 
study conducted in Sweden, a country with a strong welfare state and significant 
publicly funded health-care services, found that research participants did not view 
consent in the same way as envisaged by a traditional ethical framework. First, in 
some cases it seemed that ethical analysis focused too much on consent in relation 
to the donation of biological samples, and not enough on consent in relation to the 
supplying of biographical data. As was discussed earlier, new forms of genetic research 
(such as research into the role of SNPs and their influences on health and disease) 
require two types of information: a genetic sample, and biographical information. 
In focusing almost exclusively on the ethics of consent in relation to the donation 
of genetic samples, ethical analysis may overlook significant moral concerns in 
relation to the supplying of biographical information. In the study conducted in 
Sweden it was this latter type of information to which research participants felt most 
connected. This more personal information provided in questionnaires or interviews 
was seen as ‘more intimate’ than the genetic samples themselves.62 Secondly, research 
participants in an ongoing relationship with the health professional or public health 
authority may pay little attention to the information contained in consent forms, but 
instead place more significance on the personnel involved in the research study. This 
suggests, according to some, that decisions to donate are ‘viewed as something other 
than an information-based, intentional act’.63 Reasons for this may include a general 
desire to advance medical science, even if only one ‘single soul’ would benefit.64 
Associated with this must be the fact that the ‘altruistic’ act of donation of genetic 
samples is one that is relatively straightforward, involving only minimal risk of 
physical harm in the form of bruising to the site of venupuncture. Other studies 
have noted, too, that donation of genetic samples is sometimes seen as a ‘good deed’ 
which can be performed without significant cost to the participant.65 In the Swedish 
example, research participants were selected from those persons who were undergoing 
a State-funded health check at the ages of forty, fifty or sixty at a public health centre. 
During the examination (which involved a range of medical tests) participants 
were ‘invited’ to donate a blood sample for research purposes. Researchers in this 
type of relationship with participants should be sensitive to the special nature of 
the obligations that may arise from research conducted in the context of a pre-
existing doctor–patient relationship. In the Swedish study, research participants were 
described as already ‘enmeshed in a set of duties and responsibilities in a state–citizen 
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relationship in which healthcare plays a central role’. In this case the claim that the 
decision to donate was a decision made by an autonomous individual was criticised 
as ‘misleading’, demonstrating one way in which, in the context of genetic research, 
questions of consent pose new ethical dilemmas.66
It may be helpful to consider research as being separated into three distinct, but not 
unrelated, categories:67 research aimed at pure scientific investigation in which no 
potential benefit to the research participant is envisaged; clinical research which 
utilises and develops pharmaceuticals or other therapeutic products; and research 
which will possibly lead to a direct health benefit for the patient or their family.68 This 
helps to clarify the different relationship between the parties in each scenario. In the 
first category, the relationship is purely one of researcher and research subject. This 
is the type of scenario most likely to arise in relation to research aimed at creating 
long-term epidemiological studies of large numbers of people for the purposes of 
researching the role of polymorphisms and their association with common diseases 
(such as cancers and heart disease). This can be contrasted with the third category, in 
which the relationship is primarily one between health-care professional and patient. 
In this scenario there is a ‘therapeutic alliance’ which gives rise to stronger rights and 
duties. The primary obligation is on the health-care professional to ‘do good for, and 
not harm to, her patient’.69 It is the second scenario that arguably poses the greatest 
risk of potential conflict since the health-care professional acts as both clinician and 
researcher.70 As the World Health Organization has warned, in some investigations it 
may be easy for clinicians to ‘tip into the realm of research’, and physicians should be 
‘mindful of their dual responsibilities’.71 
Finally, one significant issue is the complex role of consent in studies involving 
‘population-specific’ research participants. While the focus of ethical guidance is on 
consent to the research by individual participants, in some cases consent should be 
sought not just from an individual participant, but also from the wider ethnic group 
or community to which that participant belongs. In these cases, researchers would 
be required to undergo consultation with the community elders or extended family, 
while also making it clear that in these circumstances an individual is ‘free to give 
or withhold consent’.72 The ethical issues in conducting population-based genetic 
research are discussed more fully later in this report. 
.  Defining ‘genetic information’: what needs protection? 
Information regarding genetic risk can potentially be of interest to many persons. It 
may be useful, for example, for insurance, in the employer–employee relationship, 
for forensic investigations, and in paternity testing. If genetic information relates to 
a group of participants connected through family relationships or under the wider 
ethnic/racial category, any misuse of information derived from a genetic study may 
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impact on that wider group. ‘There is potential for harm to participants arising 
from the use of genetic information, including stigmatization or discrimination and 
researchers must take special care to protect the privacy and confidentiality of this 
information’.73 Researchers are required to protect the privacy of participants and 
minimise any invasions of privacy. To minimise the risk of any unauthorised access to 
data researchers should take the appropriate steps to restrict access to the information, 
encrypt it and/or record it anonymously, and store it in secure facilities.74 
Public opinion surveys repeatedly reveal that behind concern about genetics is the 
belief that genetic information is ‘special’ and essentially ‘a private matter’ deserving 
of particular attention.75 The term ‘genetic information’ is not, however, a unified 
concept, although much weight has been placed on the term which has been broadly 
defined as ‘any information about the genetic make-up of an identifiable person, 
whether it comes from DNA testing or from any other source…’.76 The term may 
be applied broadly, to refer to any information that relates to any characteristic or 
condition thought to have a genetic component. According to this interpretation, 
the term ‘genetic information’ would be indistinguishable from general sorts of 
health information.77 In a narrow sense, however, the term ‘genetic information’ 
relates purely to the information derived from analysing genetic material. Under this 
narrow definition ‘genetic information’ would apply only to information resulting 
from analysis of an individual’s genetic makeup. It is helpful to separate out the main 
ways of obtaining ‘genetic information’ into the four categories listed here.78 
3.4.1  Phenotypic observation
Observing a person can provide some basic genetic information about that 
individual, derived solely from examining their appearance and characteristics.79 A 
simple example is that by observing a person’s eye colour preliminary conclusions 
can be drawn about their genetic makeup.80 While this does not pose too many 
ethical problems, some relatively serious and rare genetic conditions can give rise to 
an observable phenotypic change from which conclusions about genetic makeup can 
be implied. In the case of achondroplasia, for example, the condition is characterised 
by different body proportions from the average individual. The arms and legs are very 
short, the torso is more nearly normal size and the hands will most likely be short with 
‘stubby’ fingers, with a separation between the middle and ring fingers. From these 
observable alterations in body shape a preliminary conclusion can be drawn about 
genetic makeup. A similar judgment can occur in relation to other conditions such as 
Down syndrome (in which those affected display physical characteristics in common 
such as an upward slant to the eyes, a flat facial profile, small ears, an enlarged tongue 
and a single crease across the centre of the palms), or albinism (an inherited genetic 
condition in which the body fails to make the usual amounts of a pigment called 
melanin, causing those affected to have little or no pigment in their eyes, skin or hair). 
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While this may be a blunt tool upon which to base any genetic diagnosis, we should 
not forget that judgments based on appearance, from which genetic information is 
assumed about an individual, can be just as potentially discriminatory as the results 
of nay more sophisticated laboratory-based genetic analysis. 
3.4.2  Family history
Another way of gaining information about a person’s genetic inheritance is through 
obtaining personal and family information about medical conditions, biological inter-
relationships and descriptions of phenotypes.81 By matching this health information 
with family connectedness some preliminary conclusions can be drawn about a 
person’s genetic makeup. Take the example of Huntington disease, in which each 
offspring of a parent with Huntington disease has a 50 per cent chance of inheriting 
the gene. By obtaining a family history, one can determine that a child with a parent 
who has Huntington disease has a 50 per cent chance of also having that condition. 
If a child inherits the gene, then he or she will inherit the disease. If the child does 
not have the gene then they will neither have the condition nor pass it on to their 
subsequent offspring. The information that can be surmised from this basic medical 
and family information is that a person does or does not have a 50 per cent chance of 
having Huntington disease. This would count as ‘genetic information’ under a broad 
definition of the term; and, interestingly, these sorts of statements were possible even 
before the existence of genes was established, when all that had been proved was the 
existence of Mendel’s laws of inheritance.82
3.4.3  Laboratory-based analysis of bodily tissues and fluids
A third way through which genetic information can be obtained is the analysis in 
the laboratory of blood or other body fluids or tissues. This can be done through 
biochemical analysis of proteins or other biochemicals associated with DNA 
contained in body fluids (such as blood or urine) and tissues. Tests can be conducted 
to detect the presence or absence of the activity of the protein (as in the case of PKU), 
or of the protein itself.83 This sort of genetic information may be highly predictive 
of future health status (such as the tests for Tay-Sachs disease or cystic fibrosis), or 
it may provide evidence of a disease susceptibility that without information about 
environmental and lifestyle factors may indicate a higher than average risk only. This 
latter sort of genetic information may not be highly predictive of future health status. 
It may reveal merely a causal mechanism of disease, with the genetic element being 
but one factor that contributes to the disease progression, along with others factors 
such as environment, diet and lifestyle. Since this information is derived from a more 
complex laboratory process than the first two categories outlined earlier, it would 
count as genetic information on the narrow definition of the term, notwithstanding 
issues of vagueness in its predictability. In these cases where tests only indicate a 
 Electronic copy available at: https://ssrn.com/abstract=1828464 

susceptibility, although the laboratory testing may reveal a high level of accuracy 
about the underlying genetic condition, this ‘genetic information’ alone does not 
translate to information about future health status. This is because in these cases the 
genetic component has a relatively small degree of influence. 
3.4.4  Direct DNA or RNA analysis
A final method through which genetic information can be derived is direct analyses of 
DNA (deoxyribonucleic acid) or RNA (ribonucleic acid). A number of methods can 
be used such as sequence analysis, mutation scanning or mutation analysis to detect 
a mutation in a gene.84 One way of doing this is to test a genetic sequence by targeting 
a segment of DNA or RNA using a process known as polymerase chain reaction 
(PCR). This process (developed in 1985) allows the DNA from a single cell to be 
amplified (i.e. reproduced in large amounts) for testing.85 This method of obtaining 
genetic information is contrasted with ‘linkage analysis’ (which was previously called 
indirect DNA analysis).86 For direct analysis to be used it is necessary for the gene or 
genes (or genomic region) associated with the disorder to be known.87 This can be 
contrasted with linkage analysis, in which it is not necessary for the gene association 
to be identified. 88 
.  Protecting genetic information
As demonstrated, the first question we are presented with when we try and protect 
genetic information is the rather fundamental one of what we take that term to 
mean, and what category of information we are aiming to protect. With so many 
ways of arriving at genetic information, does the method by which we obtain genetic 
information affect the degree of protection provided? Should the term refer solely to 
conditions that are significantly influenced by genetics, or also to those conditions 
that are perceived to be influenced by genetics, despite the genetic component being 
of lesser significance than other factors?89 
Alternatively, should it refer to ‘information obtained solely from sophisticated 
methods of analysis (such as direct DNA analysis) and exclude information based 
on assessments of a more general nature (such as phenotypic observation)? In 
favour of adopting a broad definition of ‘genetic information’ is the argument that 
information about a person’s genetic heritage should be protected no matter how it is 
derived.90 Since, however, laboratory-based genetic analysis has the capacity to yield 
information not in just in relation to one, but many, conditions, and can provide 
more accurate information about our genetic makeup, the alternative argument can 
be made that it is entirely appropriate to define ‘genetic information’ narrowly, so 
that it refers solely to the results of DNA tests.91 
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Additional questions arise when we consider to what extent it is appropriate to 
separate out the types of genetic information, not by the method by which they were 
revealed, but by the personal or social significance of that information.92 The HGC 
(UK) has rightly observed that genetic information, no matter how it is arrived at, 
may either be of a highly sensitive nature to the individual, or may not be considered 
sensitive at all.93 In its report Inside Information (2002), the HGC rejected an approach 
it had tentatively favoured in its earlier work, which restricted ‘genetic information’ 
to information derived from DNA or other direct testing, in favour of a broader 
approach, in which the term, ‘genetic information’ would encompass all forms of 
genetic information howsoever derived.94 ‘We consider personal genetic information 
to be information about the genetic make-up of an identifiable person, whether 
derived directly from DNA (or other biochemical) testing or indirectly from any 
other source’.95 In reaching this conclusion the HGC is consistent with the findings of 
the International Bioethics Committee (UNESCO), which similarly recommended 
that a ‘broad rather than narrow definition of human genetic data’ was preferable.96 
The HGC was persuaded by the fact that what matters is the use – or misuse – of 
information, not how the information was derived. It argues that this places the 
emphasis on the social context of the genetic information. If genetic information is 
used to discriminate against an individual, what matters is how that discrimination 
affects the person, not whether the information was derived from direct genetic 
testing or phenotypic observation. The HGC identified four categories which were 
helpful in considering genetic information. The overlap between the categories is best 
demonstrated in Figure 1. The HGC concluded that not all personal genetic information 
should be treated the same. Different levels of protection (such as requirements of 
confidentiality and consent) differed depending on the specific circumstances. 97 
The desirability of this solution can be illustrated with the example of Duchenne 
muscular dystrophy.98 While Duchenne is a genetic condition caused by the mutation 
of a gene (called the DMD gene), it can be diagnosed in a number of different ways. 
First, due to distinct observable physical symptoms (progressive muscle weakness 
and muscle wasting, a ‘waddling’ gait and difficulty climbing stairs, and muscle 
contractures in the legs, occurring only in boys) it could be diagnosed initially 
with phenotypic observation. This may be assisted by linkage studies joining 
family history with observable phenotypic changes. Secondly, since the DMD gene 
encodes the muscle protein ‘dystrophin’, a muscle biopsy may be undertaken to assist 
diagnosis, upon which analysis is undertaken to determine whether abnormal levels 
of dystrophin occur in the muscle. Finally, DNA analysis may also be undertaken 
which may employ a variety of methods such as looking for large changes in the gene 
(deletions or duplications, for example) or other changes in gene sequencing. All 
these observations or procedures result in personal genetic information relating to 
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the same genetic condition. Adopting a definition of genetic information that protects 
this information, notwithstanding how it is arrived at, is preferable to construing the 
term narrowly. 
Figure 1: Categories of personal genetic information, showing overlap between 
observable, private and sensitve information
Source: HGC, Inside Information: Balancing Interests in the Use of Personal Genetic 
Data, May 2002, 28.
Of ethical significance to this discussion is UNESCO’s International Declaration on 
Human Genetic Data. It declares that human genetic data (defined as ‘information 
about heritable characteristics of individuals obtained by analysis of nucleic acids 
or other scientific analysis’) has a ‘special status’ (Article 4). Also provided in the 
Declaration is the specific direction that ‘every effort’ should be made to ensure 
that such human genetic data is not used in a way that infringes human rights, 
fundamental freedoms or human dignity. This applies to both the individual and to 
a family, group or community (Article 7). Article 14 sets out detailed provisions for 
the protection of privacy and confidentiality in relation to human genetic data. The 
most complex of these provisions relate to the obligation that researchers do not to 
keep such data in a form which allows the research participant to identified ‘for any 
longer than is necessary for achieving the purposes for which they were collected or 
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.  Future use of stored samples
Adding to the complexity of protecting research participants’ privacy interests, is the 
fact that, once obtained, genetic samples may be stored where they could potentially 
be used for other research. This raises questions about in what circumstances it is 
appropriate to use samples obtained for one purpose for other additional research 
purposes. There is a need for clear guidelines to protect the interests of participants 
against future unauthorised use of stored samples. The extent to which these samples 
remain in the control of the research participant is a complex legal and ethical 
problem dependent on a number of variables.99 The question has been canvassed in 
New Zealand by means of a Ministry of Health consultation in relation to proposed 
guidelines on the use of human tissue for future unspecified research purposes.100 
Since extracted DNA is not ‘human tissue’ (as currently defined in the guidelines) 
these proposed guidelines would appear to apply to genetic samples (which contain 
human cells or include a human cell) but not extracted DNA (which is the genetic 
material within the cell).101 The manner in which extracted DNA is protected is a 
separate legal question, which falls outside the scope of this report.
Regulatory complexity aside, a number of ethical issues are involved in the question of 
future use of stored samples, the most pressing of which is whether it is ever possible 
for research participants to consent to donation of samples for future research 
purposes of which they may have limited understanding, due to the ever-changing 
research in this area.102 What happens, for example, if a sample is later analysed and 
results suggest that the research participant is at risk of a genetic condition for which 
they have had no previous counselling? If samples were de-identified, the researcher 
would not be able to report back to the participant that he or she was at high risk. 
If the sample were still traceable, however, it is not clear that the researcher should 
report back in all cases. There may also be purposes for which some participants 
do not want their samples used. The current Operational Standard for Ethics 
Committees in New Zealand states that ‘consent should be obtained before human 
tissue or bodily substances may be used for any purpose other than that for which 
consent was originally given’.103 
This may mark a change in the way stored samples may be used in New Zealand. 
Previous guidance did suggest a more flexible approach, allowing that stored genetic 
samples obtained for research purposes should only be used for future research 
purposes in the following circumstances:104
(i)  The future research has the same, or closely related, research goals and the 
possibility of such future research has been discussed with the research 
participant and the participant has given consent and a new research proposal is 
submitted to an ethics committee (and approved) or,
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(ii) Genetic material and information is made anonymous and a new research 
proposal is submitted to an ethics committee and approved. 
Research participants are entitled to know at the start of the study for how long the 
data or tissue will be stored, who will be responsible for the secure storage and how 
the data or tissue will be destroyed.105 Genetic samples that have been obtained during 
routine clinical care can be used for research without the consent of the patient if the 
purpose of the research has been approved by an ethics committee.106 The current 
Operational Standard for Ethics Committees states that ethics committees may ‘waive 
the need for informed consent for storage, preservation or use of human tissue or 
bodily substances’ in cases where it is not practicable to get consent, or where the 
committee satisfies itself that ‘the potential public benefit in allowing the research to 
proceed outweighs the very strong need to protect an individual’s right to consent’. 
The guidance provides, however, that this will be uncommon and only occur in 
limited circumstances.107 This in essence echoes the guidance found in UNESCO’s 
International Declaration on Human Genetic Data. Article 16 provides that human 
genetic data collected for one purpose should not (without additional consent of the 
research participant) be used for different purposes ‘incompatible with the original 
consent’. A proviso exists, however, in cases where the proposed use ‘corresponds 
to an important public interest reason and is consistent with international law of 
human rights’. 
.7  reporting results to research participants
The current Operational Standard for Ethics Committees provides that research 
participants should ‘continue to be informed throughout the duration of their 
participation in the research or innovative practice. This includes being kept apprised 
of any developments that could potentially impact on them and being informed 
of the results of the innovative practice or research’.108 While the Human Genome 
Project has provided an unprecedented amount of genetic information, this new 
data about the human genome has not translated to a greatly improved ability to 
improve health and prevent disease.109 This ‘therapeutic gap’ (as it has been termed) 
raises significant ethical questions. What should be done with the results of genetic 
research? Is it appropriate to advise participants of results that do not translate to 
clinical treatment? Is genetic information itself valuable, irrespective of how that 
information may be used in clinical practice? While much discussion has centred 
around the potential harms in advising research participants of results which do not 
provide any firm clinical advice, there is little evidence yet of how these risks affect 
research participants and their families.
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In the case of research into conditions for which genetic influences are thought to be 
highly predictive, and which occur among close family members (such as BRCA1/2), 
it is well established that research may result in potential psychological harms to 
research participants and their families.110 In addition to psychological implications 
for the research participant and their family, genetic data arising out of research can 
also have potentially significant economic implications. For results that may be useful 
for insurance purposes the reporting back of genetic data can involve concerns about 
whether that information, once known to the research participant, must be disclosed 
to an insurer. In the United States, for example, the fear that genetic information 
about an increased risk of serious illness could harm an individual’s ‘ability to 
maintain healthcare coverage or to obtain health, life, disability or other insurance’ 
has been taken seriously. 111 Since the 1990s there have been a burgeoning number of 
legislative attempts to prevent discrimination of this kind arsing from unauthorised 
use of genetic data.112 When research participants are connected in family or other 
population groups, the potential risks from the release of information to the 
community as a whole should also be considered. At the start of any research study 
participants should be made aware of what research findings will be reported back to 
them, and the manner in which this will be done.113 When research is conducted on 
population-specific groups, the implications of reporting back should be considered 
in terms of the implications on the group as a whole. Genetic research which analyses 
the genetic information associated with an identifiable population has the potential to 
raise new risks for population groups such as indigenous communities. ‘All members 
of a socially identifiable population may be placed at risk by identification of genetic 
features linked with their common identity’.114 
  race anD genetics
The relationship between genetics and race has been described as having a ‘turbulent 
history’.115 Race itself is a contentious topic, having grown out of the European practice 
of ‘naming and organising the populations encountered in the rapid expansion of their 
empires’.116 There is currently a debate revolving around the role racial classification 
plays in medicine and biomedical research,117 and what value (if any) there is in using 
self-identified race or ethnicity to help identify factors that may contribute to health 
or disease.118 Some have argued that ‘there is no basis in the genetic code for race’, 
calling for the exclusion of racial or ethical grounds of classification in biomedical 
research.119 The terms ‘race’ and ‘ethnicity’ are themselves so loosely defined, and 
carry such ‘complex connotations’ reflecting culture and socioeconomic and political 
status, that they can appear biologically meaningless.120 Despite this, some argue that 
outward signs often associated with race and ethnicity (such as skin pigmentation, 
facial features and hair type) also indicate other differences such as character, disease 
susceptibility and temperament.121 
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At times the debate about race and genetics becomes subsumed in a larger debate 
about the role of genetics in explaining disease per se. According to Francis Collins 
(Director, National Human Genome Research Institute, United States) there is 
‘increasing scientific evidence … that genetic variation can be used to make a 
reasonably accurate prediction of geographical origins of an individual’. He cautions, 
however, that the connection is blurry ‘because of multiple other nongenetic 
connotations of race, the lack of defined boundaries between populations and the 
fact that many individuals have ancestors from multiple regions of the world’.122 
Within these parameters, genetics can play a role in health disparities associated 
with some racial or ethnic groups. This is most obvious when there is an unequal 
distribution of disease-associated alleles for recessive disorders such as sickle-cell 
disease or Tay-Sachs disease.123 Increasing research endeavours are being directed 
at understanding the role race plays in determining disease susceptibility. An 
international research project (the HapMap Project) has been established to map 
common patterns of human genetic variation. It is hoped that this will encourage 
a fuller understanding of the role genetic variation has on health and disease. The 
Project maps the genome of four different groups: European American, African (the 
Yoruba in Ibadan, Nigeria), Japanese and Han Chinese. It excludes Native Americans 
and Pacific Islanders.124 While the HapMap Project aims to identify genetic influences 
for disease and health status, it has been described as ‘naïve’ to think that the results 
would not be applied to other more contentious issues such as group identity and their 
correlation to social as well as health outcomes:125 ‘… the proposed haplotype map 
project cannot be considered in isolation from the more general, ongoing discussion 
of the implications of using socially constructed identities in genetic research’.126 
While it is true that racial categories have been misused in the past to discriminate 
against some racially defined groups, some make the case that the risks of potential 
abuses need be weighed against the potential benefits of conducting epidemiological 
and clinical research using racial and ethnic categories as criteria for ‘generating and 
exploring hypotheses about environmental and genetic risk factors’.127 
.1  race and ethnicity as indicators of disease
The greatest influence on genetic differentiation has been described as geography.128 
Distances in geographical boundaries have affected patterns of inheritance by 
directly altering patterns of mating and reproduction. This has resulted in a genetic 
substructure in some population groups that follows geographic lines.129 This has 
been noted in both indigenous groups and groups that migrated to geographically 
remote areas. Canada, for example, was one of the first countries to develop 
multidisciplinary regional genetics centres and, as early as the 1970s, Canadian 
geneticists, together with genetic counsellors and laboratory scientists, established 
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centres for providing genetic services which were specifically ‘assessed and configured 
to fit local health service requirements’.130 Many of these were created in Quebec, 
where the link between genetic disease and settlement structure is so marked that the 
‘histories of populations and the histories of their alleles’ in some ways reflect each 
other.131 French settlers to Quebec brought with them their unique genetic makeup, 
which was passed on to future generations as a result of both traditional marriage 
patterns and relative geographical remoteness. 
Figure 2: Race and Genetics – summary
Source: Collins F. What We Do and Don’t Know About ‘Race’, ‘Ethnicity’, Genetics 
and Health at the Dawn of the Genome Era. Nature Genetics Supplement 36(11), ss 
14–15, 2004
In the case of Mendelian disorders, race can have a perceptible role in the manner 
in which the conditions occur. Genetic mutations that occur less frequently than 2 
per cent are thought to be ‘nearly always race-specific’, and in some cases are found 
particularly in a single ethnic group within a wider racial classification.132 Examples 
of such groups are French Canadians, Ashkenazi Jews, Amish and ‘European gypsies’, 
all of which are thought to descend from a small number of founders.133 Conditions 
that occur with between a 2 to 20 per cent frequency are often associated with a single 
racial group. Hemochromatosis (associated with a mutant allele C282Y) occurs in all 
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groups.134 Conditions that are a more complex mix of genetic and environmental 
factors are more difficult to research, although the few examples do suggest that race 
and ethnicity still play a contributing role.135 
While this suggests that race and ethnicity can have an important role to play in 
the understanding of genetic disease, theoretical evolutionary models explaining 
how this has occurred are complex.136 Even in instances where a genetic variation 
is present in a number of ethnic groups, it may have a different effect in different 
populations. Homozygosity in the E4 variant of APO4 (associated with increased risk 
of Alzheimer’s disease) increases the risk in Japanese by a factor of 33, in Europeans 
by a factor of 15 and in African Americans by a factor of 6.137 While genetic research 
has revealed the genetic basis for a number of high-profile Mendelian (single-gene) 
disorders, using family linkage studies, this has created an ‘unrealistic expectation’ 
regarding the power of linkage studies to identify a genetic basis for common disease 
in humans.138 For these common diseases ‘no single factor is either necessary or 
sufficient’ to describe the etiology of the disease.139 
.2  researching genetic variation among mäori: examining new concepts of harm140
Although Mäori make up around only 12 per cent of the New Zealand population, 
research indicates that, compared with non-Mäori, they suffer an increased burden 
in terms of health status. Common health problems such as cardiovascular disease, 
cancer and diabetes are all more prevalent in Mäori than non-Mäori.141 One response 
to these statistics has been to seek to identify genes that might influence this greater 
disease burden. The Institute of Environmental Science and Research Limited (ESR) 
has established a strategic partnership with Mäori (Te Iwi o Rakaipaaka of the Hawke’s 
Bay) to determine their health status, develop a computerised health registry, obtain 
genetic samples and create a genetic database of up to 3000 people, who trace their 
ancestry back to the Rakaipaaka iwi.142 
This type of genetic research poses significant ethical questions, which have as yet 
been under-explored in the context of Mäori. While research into genetic variation 
has the potential to improve health in relation to these common health problems, it 
also creates new ethical challenges. Some of these potential problems have already 
come to light in New Zealand, when research (also conducted at ESR) was used by 
the researchers to identify what was described as genetic determinants for a range of 
‘antisocial disorders’ (criminality, gambling and the so-called ‘warrior gene’).143 Why 
are common health problems (such as cardiovascular disease, cancer and diabetes) 
all more prevalent in Mäori than non-Mäori?144 What accounts for this disparity? To 
what extent do genetic variations influence such health burdens? 
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First, and most importantly, health disparities can have many causes and genetics 
may have a very minor role to play. ‘In many instances, the causes of health 
disparities will have little to do with genetics, but rather derive from differences in 
culture, diet, socioeconomic status, access to health care, education, environmental 
exposures, social marginalization, discrimination, stress and other factors’.145 While 
genetic explanations may highlight some causative factors that have previously been 
overlooked, we should not forget that for most conditions health status is a complex 
result of genes interacting with environmental factors. The higher incidence of 
disease can also be attributed to basic health-care issues, such as a lack of access to 
early health care (i.e. the early detection of cancers, diabetes and heart disease) or 
a failure in education about disease prevention through changes in lifestyle. While 
new developments in genetics may encourage a deeper understanding of the role 
genetics may play in these health disparities, genetic theories of causation for health 
disparities between racial groups may overstate the importance of genetics and may 
lead researchers to miss other explanatory factors such as unequal quality of, for 
example, health care, education and employment.146 
Research in the United States, for example, demonstrates how disparities in health 
status may result from ‘long-standing, pervasive racial and ethnic discrimination’.147 
Factors such as substandard housing, increased environmental exposure to chemicals, 
hazardous working conditions and psychological stress caused by ‘perceived racial 
discrimination’ (producing higher rates of depression and high blood pressure) have 
all been cited as factors associated with poor health status in minority groups in 
the United States, contributing to a significant, non-genetic, theory of causation.148 
Notwithstanding this, to focus solely on non-genetic factors, if genetic influences 
do play a significant role in determining health status of minority groups, could be 
considered equally as problematic and raise serious ethical concerns.149
.  genetic research involving indigenous populations
Genetic research conducted on indigenous populations has been open to much 
criticism in the last decade. In the past, genetic research on indigenous groups has 
been clouded by past practices that threatened to breach a general understanding 
that biological samples would be used to help improve the health of the community, 
not prove (or disprove) theories of ancestry. A new range of harms needs to be 
considered for indigenous populations compared with other research participants 
who are usually otherwise unrelated to one another. Genetics may be used to 
question cultural beliefs and challenge claims of indigenous ancestry. They may 
be used to stigmatise further groups who are already the subject of discrimination. 
Sociopolitical harms may also arise in cases where one dominant population group 
in society uses genetic information to reinforce cultural stereotypes about a minority 
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group. These types of harms are commonplace in genetic research involving any 
sub-populations in society, but they are particularly relevant when the research 
involves indigenous populations. There have been a number of recent examples of 
genetic research being conducted in a way that both challenges cultural beliefs, and 
breaches tacit understandings between researcher and research participant. In the 
late 1990s, for example, international concern was sparked when samples from a First 
Nations group in British Columbia (Canada), which were donated by more than 800 
persons of Nuu-chah-nulth origin to examine high rates of arthritis in that group, 
were used to examine the origins of the Nuu-chah-nulth people.150 Even groups that 
have an established interest in genetic research to improve health and reduce disease 
burden can feel the negative effects of genetic research if they begin to lose control 
over how findings are disseminated and interpreted. This is demonstrated by the 
range of genetic studies being conducted on Ashkenazi Jews. While this research 
was initially welcomed and supported by the Jewish community, as more research 
demonstrated a high prevalence of mutations in Ashkenazi Jews, causing higher rates 
of breast, ovarian and colon cancers, concerns were expressed that ‘anyone with a 
Jewish-sounding name could face discrimination in insurance and employment as 
companies struggle to keep down health-care costs’.151 In response, leaders of the 
Jewish community called for guidelines to protect the community. 
These examples suggest that new types of ethical concern exist in the context 
of genetic research on population-based groups. Traditional ethical analysis of 
the potential impact of genetic information identifies problems with protecting 
confidentiality and privacy of research participants. In response to these concerns 
bioethical analysis has focused on concepts of individual autonomy and informed 
consent to safeguard against the use of genetic information for discriminatory 
purposes.152 These traditional responses have been criticised, however, for failing to 
address concerns about the potential for discrimination and stigmatisation resulting 
from what has been termed ‘population-specific genetic variation’.153 
In response to breaches of expectation new ethical guidelines have been established 
for research conducted in indigenous communities and other identifiable 
populations. Many of these guidelines are based on a model of ‘participatory action 
research’, a model which is designed both to empower those involved and recognise 
the importance of self-determination.154 There is still ongoing discussion, however, 
about the role of community involvement in the development and review of genetic 
research. On one side of the debate are those who argue that communities involved in 
population-specific genetic studies should be involved in development and ongoing 
evaluation of the research. A number of models have been proposed to facilitate 
this involvement.155 In some cases social units upon which the community already 
relies when making health-related decisions can be used to engage the community 
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in the evaluation of genetic research proposals. In other cases, alternative approaches 
may need to be found to facilitate community involvement. Contrastingly, others 
argue that these approaches for gaining community approval are impractical and of 
little real value. Moreover, attempts to do so may be construed as ‘paternalistic’ and 
‘inherently demeaning’. At the extreme end of the spectrum are those who deny any 
collective risk to socially identifiable groups.156 
Table 3: Criticism of indigenous genetic studies 
Primary areas oF criticism For genetic stuDies involving 
inDigenous ParticiPants
1.  lack of involvement of indigenous community in the planning and design   
 of research
2.  insensitivity to cultural beliefs about condition
3.  Fears about the potential for stigmatisation of community following  
 research results
4.  lack of feedback to community on completion of project
5.  Disputes about the commercial ownership of Dna
6.  General feelings of exploitation of communities
7.  concern over use of stored Dna and cell lines for unauthorised research.
Source: Arbour L. and Cook D. ‘DNA on Loan; Issues to Consider When Carrying 
Out Genetic Research With Aboriginal Families and Communities’, Community 
Genetics 9: 153-60, 2006
.  Developing a new ethical framework17 
The three central principles to consider regarding the ethics of clinical research on 
humans are respect for persons, beneficence and justice.158 This approach has been 
criticised for being too focused on individual rights, and for failing to recognise that 
research participants may be part of a wider family group or community to which 
duties are owed. Some argue that a new ethical principle needs to be adopted to 
recognise respect for wider communities and ties beyond the research participant. 
This could be a principle that confers respect on the community and an obligation on 
the investigator to ‘respect the values and interests of the community in research and, 
wherever possible, to protect the community from harm’.159 Research into specific 
sub-populations in society raises new ethical concerns. These stem from the fact 
that the effects of some research are far-reaching and transcend the confines of the 
traditional researcher–research participant relationship. While these may have been 
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overlooked in the initial stages of genetic research, targeted groups are now becoming 
aware of the need to ensure that genetic information that was intended to improve 
their health and well-being does not confer a disadvantage on the community in the 
form of discrimination, stigmatisation and the perception that the group carries a 
higher disease burden than others.160 
To date, much of the focus of research on humans has been on the potential harms 
to the research participant. The assumption is often made that research subjects are 
strangers who have no connection to each other aside from their participation in the 
research study. New forms of genetic research challenge this assumption. It is not 
uncommon for genetic research to target specific racially or ethnically defined groups. 
In these cases the potential for harms extends beyond the traditional boundaries of 
the research participant and researcher. Information about genetic risk may impact 
not only upon the individual but also upon the wider ethnic or racial group. The 
potential for stigmatisation of or discrimination towards the group subjected to the 
research is a real ethical concern. Moreover, the wider community impact of genetic 
research may be overlooked by research ethics committees, which have traditionally 
kept their focus on potential harm to the research participant. 
Ethical guidelines have been reconsidered and rewritten in an attempt to keep 
pace with new potential harms as a result of genetic research. The International 
Ethical Guidelines for Biomedical Research Involving Human Subjects (Council for 
International Organizations of Medical Sciences, 2002) provides that the investigator 
in all biomedical research involving human subjects must ensure that the ‘potential 
benefits and risks are reasonably balanced and risks are minimized’ (Guideline 8: 
‘Benefits and Risks of Study Participation’). Those investigations that are of ‘direct 
diagnostic, therapeutic or preventive benefit’ should be justified by the ‘expectation 
that they will be at least as advantageous to the individual subject, in the light of 
foreseeable risks and benefits, as any available alternative’. The guidance states that any 
risk of this kind of ‘beneficial’ intervention must be justified in relation to ‘expected 
benefits to the individual subject’. For those investigations where there is no prospect 
of ‘direct diagnostic, therapeutic or preventive benefit for the individual’, risks are 
required to be justified in relation to expected benefits to society (generalisable 
knowledge). The Guidelines state that in these cases the risks to the individual must 
be reasonable in relation to the ‘importance of the knowledge to be gained’. 
How does genetic research into the SNP variations for ethnically or racially defined 
groups fit into this framework? What if research discloses information that groups 
would rather not reveal? Traditional responses would be to suggest that individual 
research participants could withdraw from the study, or that their anonymity could 
be preserved in the publishing of genetic data; but these responses fail to address the 
concerns of a sub-population in society that may be easily identifiable even though the 
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identities of the individuals themselves are protected. In these cases, it is appropriate 
for research agreements between the research participants and investigators to be 
thorough and detailed when addressing the possibility of such information surfacing. 
Appendix 1 of the International Ethical Guidelines for Biomedical Research Involving 
Human Subjects provides that among those items to be included in a research 
protocol are the ‘circumstances in which it might be considered inappropriate to 
publish findings, such as when the findings of an epidemiological, sociological or 
genetics study may present risks to the interests of a community or population or of 
a racially or ethnically defined group of people’.161 
4.5  Conducting genetic research on mäori: new Zealand ethical standards
What the previous analysis suggests is that indigenous communities have unique 
concerns in relation to genetic research. The impact of genetic information on them 
as communities is potentially greater than the impact on other, less defined groups. 
Greater assurance needs to be given that the research will be conducted in accordance 
with robust ethical guidelines and that it will meet their expectations. Any research 
relationship must respect the indigenous cultural beliefs and be in keeping with their 
values. This extends to the use of genetic samples which may be considered ‘on loan’ 
to the researchers for the specific purpose for which consent was obtained.162 
PrinciPles oF community-BaseD ParticiPatory research 
1.  The research is required to respect the needs of the community and to be   
 considered by all parties an appropriate research question to explore
2. The research must demonstrate an acceptance of indigenous culture,   
 knowledge, tradition and values
3. respect for these cultural elements should be developed though an   
 understanding of the indigenous social, political and cultural structures
4. The indigenous community should be involved with the research from its   
 initial stages, i.e. when the research question is first asked
5. The research should offer some benefit to the community
6.  research results should be reported back and data considered to be either   
 mutually owned by the researcher and community, or owned by the   
 community with ‘data stewardship’ held by the researcher. 
Table 4: Community-based participatoy research
Source: Arbour L. and Cook D. Community Genetics 9:153–60, 2006, 2–3
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In New Zealand, any research on Mäori health burdens should take steps to minimise 
harm to Mäori arising out of the research. Researchers are required to minimise 
harms, which generally fall into four categories: physical, psychological, social, and 
economic. For research involving Mäori, researchers are additionally obliged under 
the current Operational Standard for Ethics Committees to minimise harms that 
may occur to the whänau (family or community), hinengaro (emotional well-being 
and state of mind), wairua (spirit) and tinana (the body or physical self).163 The 
concept of harm is broad enough to include ‘pain, stress, fatigue, emotional distress, 
embarrassment, cultural dissonance and exploitation’ (para 66). The New Zealand 
ethics committee guidance requires researchers to take steps to minimise potential 
harm to participants. The guidance proposes that this be achieved through inclusion 
of Mäori as ‘partners and participants in the design, implementation, management, 
and analysis of research about Mäori or Mäori health’.164 
Any research on Mäori conducted in New Zealand should be based on the following 
three principles (as set out in the Operational Standard for Ethics Committees, 
para 380): 
(i)  Partnership: working together with iwi, hapü whäau and Mäori   
 communities to ensure Mäori individual and collective rights are respected  
 and protected
(ii) Participation: involving Mäori in the design, governance, management,  
 implementation and analysis of research, especially research involving  
 Mäori
(iii)  Protection: actively protecting Mäori individual and collective rights,  
 Mäori data, Mäori culture, cultural concepts, values, norms, practices and  
 language in the research process.
The guidance describes consultation as the ‘key component’ in developing research 
on a Mäori health issue (para 381). Recalling past experiences, where consultation 
was not undertaken in a satisfactory manner, the guidance affirms that consultation 
is a ‘dynamic and flexible process’ involving a ‘two way communication process for 
presenting and receiving information before final decisions are made, in order to 
influence those decisions’ (para 382). Consultation means:
–  setting out a proposal not fully decided upon
–  adequately informing a party about relevant information upon which the  
 proposal is based
–  listening to what the others have to say with an open mind (in that there is  
 room to be persuaded against the proposal)
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–  undertaking that task in a genuine and not cosmetic manner
–  reaching a decision that may or may not alter the original proposal (para382).
The guidance also calls for Mäori participation ‘in the governance and management 
of research’, particularly research focusing on Mäori health (para 383), and for 
researchers to ensure that Mäori participants have ‘the same protection as all other 
participants in research, with particular acknowledgement of cultural diversity for 
Mäori’ (para 384). The guidance specifically states that this is to include ‘protection 
of individual and collective rights and ownership of data as well as protection from 
harm’ (para 384). Researchers are obliged to ‘support’ and ‘protect’ Mäori culture, 
language, cultural beliefs, practices, values and norms (para 384). Importantly (in 
the context of genetic research) ethics committees are asked to consider whether 
mechanisms are in place ‘to ensure the Mäori individuals and groups are not 
marginalised in the research process or by the presentation of the research results’. 
(See Appendix 2.)
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aPPenDix 1
rePort oF the First community consultation on the 
resPonsiBle collection anD use oF samPles For genetic 
research
september 2-2, 2000
Ten major recommendations for genetic research involving populations and 
communities are, in brief: 
1. Define “Community” in Appropriate and Meaningful Ways. “Community,” 
a social construct, can be defined in many different ways, and individuals may 
consider themselves members of multiple, fluid communities. Reliable criteria 
are needed for defining communities for genetic research, and all potential 
stakeholders should be included in the definition of community for a particular 
research study. 
2. Understand the Potential Benefits and Risks for Communities and 
Community Members. As much as possible, all benefits and risks should 
be identified and understood in consultation with the community during 
the planning, conduct, and followup of a research study. Special efforts may 
be needed to maximize the benefits and to minimize the risks or harms to 
communities and their members. 
3. Obtain Broad Community Input for All Phases of Research. Communities 
participating in genetic research may have a strong desire to be involved in all 
aspects and stages of the research. Researchers should give special attention to 
soliciting broad input throughout the community, and NIH should establish 
criteria, goals, and mechanisms for obtaining input from communities. 
4. Respect Communities as Full Partners in Research. Lack of reciprocity 
between communities and researchers undermines the research process. 
Effective research depends on the full participation of communities and on 
mutual respect and a continuing, interactive dialogue between researchers and 
communities. Researchers should be encouraged to be sensitive to communities’ 
perspectives and needs. 
5. Resolve All Issues Pertaining to Tissue Samples. Continued efforts are needed 
to clarify the legal status of tissue samples; establish criteria for the collection, 
use, and storage of samples; understand the potential risks and benefits for 
individuals and communities providing samples; and assure appropriate 
procedures for obtaining informed consent regarding samples. Communities 
should participate fully in these efforts. 
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6. Establish Appropriate Review Mechanisms and Procedures. Researchers are, 
and should be, held accountable for any research involving communities. NIH 
should ensure the transparency of this research to communities and foster the 
participation of communities, public advisory groups, and institutional review 
boards in initial and ongoing reviews of community-based research studies. 
7. Facilitate the Return of Benefits to Communities. Communities participating 
in research often do not believe that they receive any benefits, or returns, from 
their participation. Researchers should make an effort to provide these benefits, 
and NIH should extend support for follow-up studies of the benefits of research 
for communities and their members. The ownership of research results and data 
needs to be clarified. 
8. Foster Education and Training in Community-Based Research. To enhance 
researchers’ understanding and skills for conducting community-based 
genetic research, support is needed for education and training of predoctoral 
investigators and for continuing education for established investigators and 
research reviewers. Curricula should include community issues; ethical, legal, 
and social implications of genetic research; and model programs. 
9. Ensure Dissemination of Accurate Information to the Media and Public. 
NIH should disseminate widely the results of genetic research which shows that 
genetic variation within populations is greater than that between populations; 
foster education of health professionals about these findings; and promote 
dialogue with the public about the ethical, legal, and social implications of 
genetic research. 
10. Provide Sufficient Funding and Encourage Partnerships. NIH should provide 
sufficient funding to ensure that meritorious community-based genetic research 
can be conducted adequately. Specifically, NIH should expand funding to foster 
community involvement and participation in this research and encourage 
partnerships among government, industry, and academia.
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aPPenDix 2
ministry oF health, OPERATIONAL STANDARD FOR ETHICS 
COMMITTEES: aPPenDix  research involving mÄori 
ministry of health 200
376. This appendix has drawn on a number of publications including those produced 
by the purchasers of Mäori research and Mäori researchers themselves. Source 
documents are referenced in the Bibliography.
377. The National Ethics Advisory Committee is currently developing a Mäori
framework for ethical review of health and disability research. For further information 
on this work see www.newhealth.govt.nz/neac.
378. Mäori health research practice and theory is developing rapidly. A number of
guidelines and standards for undertaking research with and about Mäori have been 
developed over the years. Examples include the Health Research Council Guidelines 
for Researchers on Health Research Involving Mäori, Pomare et al (1995) Hauora: 
Mäori Standards of Health III, and the Hongoeka Declaration for Mäori Health 
Researchers (refer to Te Pumanawa Hauora ki Te Whanganui-a-Tara (ed) (1996). 
Hui Whakapiripiri: A Hui To Discuss Strategic Directions for Mäori Health Research 
(Wellington: University of Otago). Many of the issues important to Mäori researchers 
and research participants are covered in the text of this document. Other issues which 
should also be considered include:
•  the Rights of Indigenous Peoples over their cultural and intellectual property  
 (the Mataatua Declaration, UN Commission of Human Rights (1993))
•  the recognition of diverse Mäori realities
•  the opportunity for Mäori to monitor, critique, and discuss, including in hui  
 and public forums, all research impacting on Mäori health
•  the strengthening and development of Mäori health researchers.
379. Other indigenous approaches are important comparators to the Mäori research 
developmental approach and this is reflected in a recent agreement on indigenous 
health research between New Zealand, Canada and Australia (Canadian Institutes 
of Health Research, National Health and Medical Research Council of Australia, and 
Health Research Council of New Zealand, 2001).
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Principles
380. The three Treaty of Waitangi principles of partnership, participation and
protection should inform the interface between Mäori and research.
•  Partnership . working together with iwi, hapü whänau and Mäori
 communities to ensure Mäori individual and collective rights are respected
 and protected.
•  Participation . involving Mäori in the design, governance, management,
 implementation and analysis of research, especially research involving Mäori.
•  Protection . actively protecting Mäori individual and collective rights, Mäori  
 data, Mäori culture, cultural concepts, values, norms, practices and language  
 in the research process.
Partnership
381. Consultation is a key component in the development of research on a Mäori
health issue and for involving Mäori as partners and participants in the research
process.
382. In the past there have been many instances of misunderstanding resulting from 
differences in opinions as to what constitutes consultation. Consultation is a two 
way communication process for presenting and receiving information before final 
decisions are made, in order to influence those decisions. It is a dynamic and flexible 
process, which is well summarised by Justice McGechan: .Consultation does not 
mean negotiation or agreement. It means:
•  setting out a proposal not fully decided upon
•  adequately informing a party about relevant information upon which the  
 proposal is based
•  listening to what the others have to say with an open mind (in that there is  
 room to be persuaded against the proposal)
•  undertaking that task in a genuine and not cosmetic manner
•  reaching a decision that may or may not alter the original proposal.
Participation
383. Mäori participation in the governance and management of research must also 
be enabled. Participation by Mäori in the research process is especially important 
in research that focuses on Mäori or Mäori health. The full range of research 
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methodologies may be applied to Mäori and Mäori health. This range covers many 
innovative approaches, especially including kaupapa Mäori methodologies, which 
have been developed by Mäori researchers and Mäori research units.
Protection
384. Mäori participants must be afforded the same protection as all other participants 
in research, with particular acknowledgement of cultural diversity for Mäori. This 
includes protection of individual and collective rights and ownership of data as 
well as protection from harm. In addition, Mäori culture, language, cultural beliefs, 
practices, values and norms must also be supported and protected. Te reo Mäori, one 
of New Zealand.s two official languages, is a special case in point, as are the respective 
roles and rights of Mäori collectives whänau, hapü, and iwi, and individual Mäori.
informed consent
385. While written consent is the usual method of recording informed consent in
research, some Mäori may prefer to give their consent orally.
Points to consider
386. Ethics committees should consider the following points.
•  Are mechanisms in place to ensure that Mäori are involved as research 
participants in ways that do not undermine their cultural integrity?
•  Are there any special problems, such as confidentiality and reporting, that might 
arise in sensitive research such as research about child abuse or sexual practices 
of rangatahi?
•  Are special needs of rangatahi Mäori, such as counselling and confidentiality, 
accounted for in the research design?
•  When is it appropriate for parents or other whänau members to be present 
during the conduct of the research?
•  If conditions present in participants have implications for other whänau 
members. health statuses, are appropriate mechanisms proposed for dealing 
with the larger family unit (for example, genetic risks or HIV infection)?
•  Are mechanisms in place to ensure that tikanga Mäori will be observed?
•  Are mechanisms in place to ensure the Mäori individuals and groups are not 
marginalised in the research process or by the presentation of the research 
results?
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